The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib

L Porcelli, E Giovannetti, YG Assaraf… - Current drug …, 2014 - ingentaconnect.com
… inhibitor Ko143 did not increase erlotinib sensitivity, but did … of BCRP expression, trafficking
and drug transport activity. These … of erlotinib with drugs that are BCRP transport substrates. …

Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib

YH Ling, T Li, R Perez-Soler, M Haigentz - Cancer chemotherapy and …, 2009 - Springer
erlotinib and tunicamycin in human NSCLC cell lines which can be exploited in clinical studies
of novel drug combinations with erlotinib. … After blocking with 5% bovine serum albumin in …

Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro

P Biegański, M Godel, C Riganti, DF Kawano… - Bioorganic …, 2022 - Elsevier
erlotinib and other target therapy drugs the lung cancer treatment have improved a lot in recent
years. However, erlotinib-… of erlotinib together with their anticancer activity studies against …

Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver

G Varan, S Akkın, N Demirtürk, JM Benito… - Journal of drug …, 2021 - Taylor & Francis
Drug Administration (FDA) [Citation2]. ERL is available in oral tablet form under the trade
name Tarceva ® … As with most anticancer drugs, poor water solubility brings many drawbacks, …

Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy

K Saravanakumar, A Sathiyaseelan… - Carbohydrate …, 2020 - Elsevier
… The drug loading, and entrapment efficiency of erlotinib in CSNPs was determined at
absorbance of 346 nm using the high-performance liquid chromatography (HPLC). …

Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib

A Avan, AD Adema, EK Hoebe, CM Huijts… - Current drug …, 2014 - ingentaconnect.com
… After blocking the arrays with 2% bovine serum albumin (BSA) and subsequent loading of the
… Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma

Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects

HG Choi, JY Jeon, YJ Im, Y Kim, EK Song… - Clinical drug …, 2015 - Springer
… [47], the data in this study are a valuable addition to the field of drug development. This
study suggests that the test and reference formulations of erlotinib 150 mg have similar …

[HTML][HTML] … of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient …

RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific reports, 2017 - nature.com
erlotinib/RAPTA-C combination by identifying effective drug dose ratios and studying the
mechanism of action of this drug … The membrane was blocked with 5% bovine serum albumin in …

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

MD Prados, KR Lamborn, S Chang, E Burton… - Neuro …, 2006 - academic.oup.com
… Growth factors, erythropoietin, new CYP3A/4 inhibitors, and other investigational drugs were
not permitted nor was previous use of erlotinib. All patients signed an informed consent form…

The role of Self-Nanoemulsifying drug delivery systems of CDODA-Me in sensitizing Erlotinib-Resistant non–small cell lung cancer

E Nottingham, V Sekar, A Mondal, S Safe… - … of pharmaceutical …, 2020 - Elsevier
… treatment involving ERL (erlotinib) with a glycyrrhetinic acid … using self-nanoemulsifying
drug delivery systems (SNEDDS). … to optimize drug content, particle size, and drug release. …